Is Sanofi's Ouster of Viehbacher a Mistake?
Sanofi has jettisoned its long time CEO, but that might not be the best decision given challenges that lay ahead.
Could MannKind Corporation Be Running Out of Money?
A biotech stock running out of money is perhaps the biggest concern healthcare investors have. Find out if MannKind has the cash on hand to successfully execute on its business strategy.
Insuline: Significant Upside, Alternative Diabetes Play With A Population Based Cost-Reduction Platf
Insuline: Significant Upside, Alternative Diabetes Play With A Population Based Cost-Reduction Platform In Diabetes
Forget MannKind Corporation: 3 Better Stocks
Three Motley Fool analysts weigh in on which companies they think are better bets than MannKind.